Currentmedical mutual - ohioPolicy N/A

Leuprolide Immediate Release (IR)

Prior authorization guidance for coverage of leuprolide immediate release products for Medical Mutual - Ohio members; describes approved indications, required documentation, and approval durations affecting prescribers and pharmacies.

Policy Summary

Payermedical mutual - ohio

PolicyLeuprolide Immediate Release (IR) — Prior authorization guidance and coverage criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateOct 16, 2026

Key ActionSubmit prior authorization with required documentation (chart notes, prescription claims, receipts) when trials of other agents are required.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yrInitial approval duration

1 yrExtended approval duration

≥6Indications addressed

AnnualPolicy review cadence

Coverage Criteria — When Leuprolide IR Is Authorized

FDA-approved indications: Prostate cancer; Central Precocious Puberty (CPP)

Approve for these FDA indications

Other supported uses: Ovarian cancer; Female infertility (approve only if member has fertility coverage and all subcriteria met); Prophylaxis or treatment of uterine bleeding in patients with hematologic malignancy or prior to BMT/SCT; Uterine leiomyoma

See female infertility subcriteria

Female infertility subcriteria: i) Requested by an appropriate fertility specialist; AND ii) The woman does not have evidence of inadequate ovarian reserve from any of the following: abnormal CCCT OR elevated day 3 FSH OR abnormal AMH or antral follicle count OR age >= 44 years; AND iii) Tubal obstruction is ruled out; AND iv) An abnormal semen analysis is ruled out; AND v) Ovulatory dysfunction is ruled out; AND vi) An inoperable uterine cavity abnormality is ruled out.

Member must have fertility coverage to approve

Coverage is not recommended for uses that are not listed in the Recommended Authorization Criteria. Requests for indications outside the criteria will be reviewed case‑by‑case for efficacy and medical necessity, and criteria will be updated as new published data become available.

Leuprolide immediate release products will not be authorized for fertility indications when the member does not have plan fertility coverage.

Leuprolide IR has not been shown to be effective for, or has only limited/preliminary data or potential safety concerns for, conditions not listed in the Recommended Authorization Criteria. The list of conditions not recommended for approval is illustrative and not exhaustive; requests for such uses may be denied unless sufficient evidence of efficacy and medical necessity is provided.

Provider Actions, Documentation & Denials

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended for pharmacy benefit coverage of leuprolide immediate release products. Approval is recommended only for members who meet the coverage criteria and initial/extended approval conditions in this policy. Leuprolide long-acting formulations follow a separate prior authorization policy. Leuprolide will not be authorized for fertility indications if the member does not have plan fertility coverage.

Applies to immediate-release leuprolide products (e.g., Lupron and generics)

Documentation Required

Trial Documentation for Certain Indications

For certain indications (for example, some infertility and other specified uses), approval requires documentation of trials of other agents or diagnostic evaluations as listed in the coverage criteria. Examples in this policy include requirements related to fertility evaluation (ovarian reserve testing, tubal patency, semen analysis, ovulatory function, uterine cavity assessment) and other indication-specific prerequisites.

Ovarian reserve assessment (clomiphene citrate challenge test, day 3 FSH, anti-Mullerian hormone or antral follicle count) when indicated
Tubal obstruction ruled out
Normal or addressed semen analysis
Ovulatory dysfunction ruled out
Inoperable uterine cavity abnormality ruled out

Documentation Required

Required Documentation

When documentation is required, the prescriber must provide written evidence supporting trials of the other agents or required evaluations. Acceptable documentation includes chart notes, prescription claims records, prescription receipts, test results, and other relevant medical records. The Company may request additional documentation and will consider submitted records when determining medical necessity.

Chart notes documenting prior therapy or evaluations
Prescription claims records or receipts showing prior agent trials
Relevant laboratory or imaging results
Provider credentials or notes as requested

Denial Risk

Denial Conditions

The Company may deny reimbursement or authorization if the drug or service is determined to be not medically necessary, investigational or experimental, outside the scope of the member's benefits, or if required documentation is not provided. Requests for uses not listed in this policy will be reviewed case-by-case for evidence of efficacy and medical necessity.

Denial possible for missing or insufficient documentation
Denial possible for investigational or not medically necessary uses
Denial possible if use is outside member benefits (e.g., fertility care not covered)

Continuation / Extended Approval Criteria

Extended Approval

Continuation/Extended Approval: Extended approval duration: 1 year (365 days)

Same duration as initial approval

Step Therapy and Required Trials

Requirement	Prescriber supporting documentation
Documentation of trials of other agents when noted in criteria
Chart notes, prescription claims records, and/or prescription receipts must be provided by the prescriber to support trials of other agents as specified in the criteria

Definitions & Mechanism

Leuprolide (mechanism) — GnRH agonist mechanism summary

Drug classGnRH (gonadotropin-releasing hormone) agonist (synthetic nonapeptide analog)

Mechanism — initial effectSingle daily doses cause an initial increase in LH and FSH, producing a transient rise in sex steroids (testosterone in males; estrone/estradiol in premenopausal females)

Mechanism — continuous administrationWhen administered continuously at therapeutic doses, leuprolide suppresses LH and FSH, leading to decreased ovarian and testicular steroidogenesis

ReversibilitySuppression of gonadal steroidogenesis is reversible after drug discontinuation

Pharmacologic noteLeuprolide is more potent than endogenous GnRH and functions as a potent inhibitor of gonadotropin secretion with chronic dosing

Background Information

Leuprolide is a GnRH agonist that, with continuous administration, initially stimulates then suppresses luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This sustained suppression leads to reversible reduction of ovarian and testicular steroidogenesis, and is the pharmacologic basis for its use in conditions where decreased sex steroid production is therapeutic.